Details of the Drug

General Information of Drug (ID: DM62QTW)

Drug Name
RTB101
Indication
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Phase 3 [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [2]
Drug Type
Small molecular drug
Cross-matching ID
PubChem CID
11977753
TTD ID
DFY58O
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CREB-regulated transcription coactivator 1 (TORC1) TT4GO0F CRTC1_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
3 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.